Subbiah V, Hu MI, Mansfield AS, Taylor MH, et al. Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid 2023 Nov 27. doi: 10.1089/thy.2023.0363.
PMID: 38009200